INTRODUCTION: @entity1832 ( @entity1832 ) and @entity751 ( @entity751 ) are atypical @entity4652 with @entity73 as common features. While @entity1833 are a good predictor of Lewy body pathology and are rare in @entity751 , they are not exhibited in all cases of @entity1832 . Given the clinical overlap between these disorders, neuropsychological and imaging markers may aid in distinguishing these entities. METHODS: Prospectively recruited case-control cohorts of @entity751 (n =31) and @entity227 (n =30), completed neuropsychological and neuropsychiatric measures as well as brain perfusion single-photon emission computed tomography and structural magnetic resonance imaging (MRI). Perfusion data were available for forty-two controls. Behavioural, perfusion, and cortical volume and thickness measures were compared between the groups to identify features that serve to differentiate them. RESULTS: The Lewy body with no hallucinations group performed more poorly on measures of episodic memory compared to the corticobasal group, including the delayed and cued recall portions of the California Verbal Learning Test (F (1, 42) =23.1, P <0.001 and F (1, 42) =14.0, P =0.001 respectively) and the delayed visual reproduction of the Wechsler Memory Scale-Revised (F (1, 36) =9.7, P =0.004). The Lewy body group also demonstrated reduced perfusion in the left occipital pole compared to the corticobasal group (F (1,57) =7.4, P =0.009). At autopsy, the Lewy body cases all demonstrated @entity303 with @entity1832 , @entity195 , while the corticobasal cases demonstrated classical @entity528 in five, @entity303 with agyrophilic grains   +   @entity528   +   @entity8267 in one, @entity7463 in two, and Frontotemporal Lobar Degeneration-Ubiquitin/ @entity529 @entity17251 in one. MRI measures were not significantly different between the @entity1 groups. CONCLUSIONS: Reduced perfusion in the left occipital region and worse episodic memory performance may help to distinguish between @entity1832 cases who have never manifested with @entity1833 and @entity751 at earlier stages of the disease. Development of reliable neuropsychological and imaging markers that improve diagnostic accuracy will become increasingly important as disease modifying therapies become available.

Differentiating between @entity1833 -free @entity303 with XXXX on the basis of neuropsychology and perfusion single-photon emission computed tomography.

@entity8267 :: ('MESH:D016657', 'Disease') :: ['cerebral amyloid angiopathy'] @entity1 :: ('9606', 'Species') :: ['patient'] @entity227 :: ('MESH:D014786', 'Disease') :: ['visual hallucination-free DLB'] @entity4652 :: ('MESH:D020734', 'Disease') :: ['parkinsonian disorders'] @entity73 :: ('MESH:D003072', 'Disease') :: ['fronto-subcortical and posterior cognitive dysfunction'] @entity303 :: ('MESH:D003704', 'Disease') :: ['dementia', 'mixed dementia'] @entity17251 :: ('MESH:C563476', 'Disease') :: ['proteinopathy'] @entity1833 :: ('MESH:D006212', 'Disease') :: ['visual hallucinations'] @entity1832 :: ('MESH:D020961', 'Disease') :: ['Lewy bodies', 'DLB', 'Dementia with Lewy bodies'] @entity751 :: ('MESH:D013577', 'Disease') :: ['CBS', 'Corticobasal Syndrome'] @entity195 :: ('MESH:D000544', 'Disease') :: ["Alzheimer's disease and small vessel arteriosclerosis"] @entity7463 :: ('MESH:D013494', 'Disease') :: ['Progressive Supranuclear Palsy'] @entity529 :: ('23435', 'Gene') :: ['TAR DNA-binding protein 43'] @entity528 :: ('MESH:D009410', 'Disease') :: ['corticobasal degeneration']
@entity1832 :: (MESH:D020961,Disease) :: ['Lewy bodies and corticobasal syndrome']
